newsfilter
← Latest News
Business Wire·

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

  • AtriCure, Inc. will participate in the 2026 Wells Fargo Health Care Conference.
  • Management will hold a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time.
  • A live audio webcast of the event will be available via the "Investors" section of AtriCure's website.
  • AtriCure treats conditions affecting over 59 million people worldwide, including atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain.
  • The Isolator® Synergy™ Ablation System holds FDA approval as the first device for persistent Afib treatment.
  • AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices globally.
  • Hybrid AF™ Therapy offers a minimally invasive solution for long-standing persistent Afib patients.
  • cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary nerve ablation to manage pain in cardiac, thoracic, and amputation procedures.